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Molecular imaging using PET/CT or PET/MRI has evolved from an experimental imaging
modality at its inception in 1972 to an integral component of diagnostic procedures in
oncology, and, to lesser extent, in cardiology and neurology, by successfully offering in-
vivo imaging and quantitation of key pathophysiological targets or molecular signatures,
such as glucose metabolism in cancerous disease. Apart from metabolism probes, novel
radiolabeled peptide and antibody PET tracers, including radiolabeled monoclonal
antibodies (mAbs) have entered the clinical arena, providing the in-vivo capability to
collect target-specific quantitative in-vivo data on cellular and molecular
pathomechanisms on a whole-body scale, and eventually, extract imaging biomarkers
possibly serving as prognostic indicators. The success of molecular imaging in mapping
disease severity on a whole-body scale, and directing targeted therapies in oncology
possibly could translate to the management of Coronavirus Disease 2019 (COVID-19), by
identifying, localizing, and quantifying involvement of different immune mediated
responses to the infection with SARS-COV2 during the course of acute infection and
possible, chronic courses with long-term effects on specific organs. The authors
summarize current knowledge for medical imaging in COVID-19 in general with a focus
on molecular imaging technology and provide a perspective for immunologists interested
in molecular imaging research using validated and immediately available molecular
probes, as well as possible future targets, highlighting key targets for tailored treatment
approaches as brought up by key opinion leaders.
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INTRODUCTION
In response to the current pandemic of Coronavirus Disease 2019,
medical imaging research first focused on procedure and safety
guidelines and the integration of medical imaging into the
diagnostic workflow for COVID-19 (1–4). In the meantime, the
spectrum of associated symptoms attributed to the disease has
become larger, clearly exceeding the notion of it being primarily a
severe pneumonia with fever, cough and dyspnea, thus warranting
to extend medical imaging to provide information not only on
pulmonary condition. Early observational studies reported older
age and the presence of comorbidities as risk factors for increased
disease severity. With increasing incidence of COVID-19, an
increasing number of severe courses of disease have been
reported in younger patients with no pre-existing, medical
conditions (5). Acute respiratory distress syndrome (ARDS) is a
common complication of severe viral pneumonia, and is reported
to occur in 15.6% of patients with severe COVID-19
pneumonia (6).
Accumulating evidence suggests that some of the detrimental
effects seen in patients with COVID-19 is attributed to an overly
host antiviral defense as described earlier in severe acute
respiratory syndrome (SARS), leading to hyperinflammatory
reactions (7) or cytokine storm syndrome, sometimes
culminating to affect the central nervous system (CNS) (8),
and often associated with increased serum levels of several
inflammatory cytokines and chemokines (9).
There is also an increasing number of COVID-19 associated
cases with systemic or localized inflammatory disease, such as
vasculitis (10), endothelial cell dysfunction (11), Kawasaki-like
disease in the young (12), nephritis (13), Guillain–Barré-
syndrome (14) or inflammatory bowel disease (15), with no
indication of lab findings, clinical signs, or symptoms
predictive of their appearance. The factors that ultimately
trigger severe illness in individuals infected with SARS-CoV-
2 are not completely understood and as in other systemic
inflammatory conditions, the development of severe disease
may be preceded by signs of locally contained inflammatory
reactions, occult to clinical observation, but possibly visible by
molecular imaging.
In a recent comment, Merad et al. appealed “to start
measuring longitudinally and with as much granularity as
possible the systemic and potentially local inflammatory
responses induced by SARS- CoV-2 and how these pathways
are modulated by the different therapies currently used as
standard of care or in clinical trials, [ … ] clinical centers that
have the means to perform deep-monitoring studies now have
the responsibility to conduct such studies and to share their
strategies and results with the scientific community”. In this
article, the authors present their position on how molecular
imaging for COVID-19 fits to this appeal and why it should
widely be used by immunologists.
GENERAL CLINICAL CONTRIBUTION OF
MEDICAL IMAGING TO LONGITUDINALLY
INVESTIGATE COVID-19
Medical imaging, in certain, clinical settings being on the
frontline of diagnostics in COVID-19 (4, 16, 17), is able to
provide objective, longitudinal measures of both systemic and
local disease involvement. During the unfolding of the
pandemic, chest-CT scanning has grown into a clinically
well-established procedure in the early diagnosis of
COVID-19 in patients with symptoms ranging from none to
very severe (3). Depending on the diagnostic workflow of an
individual institution, CT may well be a very initial diagnostic
procedure, in some situations even preceding PCR diagnostics
(18, 19), and accordingly, CT has been integrated into
various diagnostic algorithms for COVID-19 (4, 20). Recent
progress in clinical applications of artificial intelligence
(AI) in COVID-19 (21–23) has led to approval of first
clinical products for AI-based, automated detection of
COVID-19 related changes in chest-CT, integrating
differentiation criteria not always obvious to the eye of less
experienced observers.
By current recommendations of the American and
European Radiological Societies, computed tomography (CT)
of the chest is indicated in COVID-19 patients with respiratory
symptoms and may be helpful in patients with milder
symptoms but co-morbidities, with repeat CTs indicated in
cases with suspected complications (e.g. superinfection,
pulmonary embolism) (24).
With systematic data just being built up, however, it still
remains fluent, to which extent imaging studies add to the
clinical management of COVID-19 and its complications.
Current notion includes that specific exams might add to
clinical understanding in selected cases as in suspected
myositis, perimyocarditis or possible CNS involvement
(25, 26).
As a subgroup of COVID-19 patients that seems to do well
after getting out of the intensive care unit, dies of acute
respiratory syndrome just several days later, without clinical
signs indicating their imminent deterioration, systematic
whole-body imaging data on the inflammatory burden
during the course of disease, including a refractory phase
after intensive care, could be a potential life-saver for
individual patients.
Abbreviations: COVID-19, Coronavirus disease 2019; SARS-CoV-2, Severe acute
respiratory syndrome coronavirus 2; ARDS, Acute respiratory distress syndrome;
CT, Computed tomography; AI, Artificial intelligence; FDG, Fluordeoxyglucose;
PET, Positron emission tomography; MRI, Magnetic resonance imaging; CNS,
Central nervous system; RIG-I, Cytosolic retinoic acid-inducible gene I; RLRs,
RIG-I like receptors; TLRs, Toll-like receptors; IFNs, Interferons; CXCR4, C-X-C
Motif chemokine receptor 4, also: chemokine-receptor type 4; ATP,
Adenosinetriphosphate; P2X7, ATP-purinergic receptor P2X7, also: P2X
purinoceptor 7; FAP, Fibroblast activation protein; ACE-2, Angiotensin-
converting enzyme 2; ATR1, Angiotensin-II-receptor type 1; COX-2,
Cyclooxigenase-2; NSAIDs, Non-steroidal anti-inflammatory drugs; COX-1,
Cyclooxigenase-1; CD-8+, Cluster of differentiation 8 antigen positive; NK-cells,
Natural killer cells; uEXPLORER, Ultra-High-Resolution total-body digital PET/
CT with 194 cm axial field of view; UCDavis, University California, Davis;
PennPET, Pennsylvania University whole-body digital PET/CT with 64 cm axial
field of view; WHO, World Health Organization.
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RATIONALE FOR AND POTENTIAL
OF SYSTEMATIC CLINICAL STUDIES
ON TARGETED MOLECULAR IMAGING
USING POSITRON EMISSION
TOMOGRAPHY IN COVID-19
The scientific response to COVID-19 has been extraordinary,
with a plethora of studies designed to rapidly unravel the
pathogenesis of COVID-19 and potential therapeutic strategies,
often posted in preprint servers to speed up access to the
scientific community. While preclinical in-vitro and in-vivo
data has rapidly accumulated and undoubtedly plays an
important role in anticipation and design of clinical studies
and future, prospective clinical trials, the need for human
in-vivo-evidence for the applicability of proposed therapeutic
strategies is still unmet and evolving.
MRI and PET/CT are the two key imaging modalities that
have been investigated extensively for providing non-invasive
information on localization and extent of inflammatory disease
and disease of autoimmune origin (27, 28), with MRI being the
most frequently used modality and whole-body PET/CT yielding
the highest sensitivity and specificity even for clinically occult
disease [for review (29)].
The exquisite sensitivity of PET imaging is based on the tracer
principle, where radiopharmaceuticals designed to specifically
aim a physiological target are introduced into the patient and are
subsequently detected by quantitative counting of positron
emissions originated by their radioligand, allowing for
localization and visualization by computed reconstruction of
their spatial distribution. PET thus allows for observing and
quantifying molecular signatures as targeted by the
radiopharmaceutical, non-invasively, in vivo, with a resolution
in the space domain in the range of millimeters and in the time
domain in the range of seconds to a couple of days or even weeks,
depending on the specific half-life of the radionuclide coupled to
the carrier molecule.
As defined by the tracer principle, the amount of carrier-
target-complex injected is always below the threshold of a
pharmacological effect, with a sensitivity of the method
allowing for quantitation of picomolar to nanomolar
concentrations (30). The technological evolution of combining
advanced PET detectors and CT into one single hybrid scanner
has led to scanning times down from an initial hour-long
procedure to whole-body scans feasible in a couple of seconds,
having allowed a widespread clinical adoption of PET for
oncologic indications and facilitating imaging procedures even
in the severely i l l . The most frequently used PET
radiopharmaceutical to date is 18-F-Fluorodeoxyglucose
(FDG), targeting the glucose transporter 1 (GLUT-1), which is
overexpressed in many malignant cells, but also in cells
responsible for inflammatory response.
The increased availability of the technology over the past two
and a half decades of its clinical implementation has also
broadened its clinical applications, and imaging of inflammatory
disease, e.g. in large vessel vasculitis, autoimmune encephalitis or
fever without origin, are now established indications for
FDG-PET/CT (29, 31–33). More recently, hybrid molecular
imaging using FDG-PET/MRI has attracted attention for
combining the superb imaging characteristics of both, MRI and
PET in a simultaneous exam, defining a new imaging gold
standard (34) with increasing sensitivity and specificity in soft
tissue pathologies.
Early case series in COVID-19 patients indicate that whole-
body FDG-PET/CT is highly sensitive for detection and
quantification of inflammatory pulmonary involvement (35), as
well as extrapulmonary inflammatory disease, e.g. in lymph
nodes, intestine or implant sites of interventional cardiac
devices (36–40). Given the high diagnostic accuracy for
FDG-PET/CT in substantiating localized inflammation on a
whole-body level even in early stages of inflammatory disease
(29), and the broad availability of the modality in North and
Latin America, Europe, Asia and Oceania with a heterogenous
availability in Africa (41), it would be an easy-to-accomplish task
to conduct prospective, longitudinal, multicentric studies in
COVID-19 patients at different stages of severity, to a) identify
extrapulmonary inflammatory disease manifestations and b)
search for possible imaging biomarkers of later severe and
potentially life-threatening inflammatory reactions, thus
possibly identifying individuals in need of specific anti-
inflammatory treatment.
While FDG is themost frequently used PET radiopharmaceutical
to date, the intrinsic ability of PET to provide tailored targeted
molecular imaging has drawn interest from a growing body of
medical specialties, including immunology, where radiolabeled
monoclonal antibodies (mAbs) and intermediary compounds of
the immunological response have been successfully introduced and
are summarized under the term Immuno-PET (42–46). Close
collaboration between radiopharmacists, radiochemists, clinicians,
and nuclear medicine specialists has increased the number and
species of radiotracers, with an exquisite pool of established and
conceptionalized radiolabeled biomarkers bearing the unique
potential of providing primary quantitative data on cellular or
even molecular level on a whole-body scale, allowing for a
pictorial whole-body cartography of the process under
investigation. As current PET imaging has almost completely
turned into hybrid imaging, either diagnostic CT or MRI will be
acquired along with the PET investigation and thus offers an
unparalleled view into the pathophysiological changes associated
with an individual course of disease.
In comparison to standard immunological testing, which also
provides longitudinal information of inflammatory disease in
COVID-19, whole-body imaging adds the anatomical
localization of the pathophysiology, which may prove clinically
relevant for the assessment, targeted treatment and follow-up of
organ-specific disease such as myocarditis, pericarditis,
inflammatory bowel disease, pancreatitis and chronic
inflammatory disease or vascular inflammation (47).
As each diagnostic receptor binding site also inherently
represents a possible target site for newly developed or
repurposed therapeutic agents, simultaneous therapeutic
application during an imaging study poses an intrinsic
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displacement challenge for its diagnostic twin, with dynamic
imaging allowing for a quantitative, summative monitoring of
treatment effect based on cellular level.
The whole potential of PET/CT or PET/MRI, however, can
only unfold in an interdisciplinary collaboration of the related
disciplines of immunology, virology, clinical medical specialties,
pathology and nuclear medicine, and requires a dedicated effort
to establish controlled clinical study protocols using a wise
selection of rapidly available radiopharmaceuticals (48). Such
an effort would allow the medical specialties involved to make
best use of the full potential of molecular imaging to identify key
pathogenic mechanisms, to quantify disease process and to





Chemokines and Chemokine Receptors
An excessive inflammatory response to SARS-CoV-2 at a given
timepoint of the disease, often in its later stages, is thought to be a
major cause of disease severity and death in patients with
COVID-19 and is associated with high levels of circulating
cytokines, profound lymphopenia and substantial mononuclear
cell infiltration in the lungs, heart, spleen lymph nodes and
kidneys, as observed in post-mortem analysis (49).
In the absenceof preexisting antibodies to a viral infection, innate
immune sensing triggers a pathway of specific immune responses as
a first line of antiviral defense. While data on the specific innate
immune response toSARS-CoV-2 is still limited, a certain analogy to
the well-studied immune responses to other coronaviruses may be
expected, where cytosolic retinoic acid-inducible gene I (RIG-I) like
receptors (RLRs) and extracellular and endosomal toll-like receptors
(TLRs) trigger signaling cascades resulting in the secretion of
cytokines (49) and have shown to sit at the crossroads of multiple
inflammatory pathways including neuroinflammatory disease (50).
Early antiviral defense is mediated by type I/III interferons (IFNs),
followed by inflammatory cytokines and chemokines. Immune cell
profilingofCOVID-19patients in the recovery stagehas shownhigh
expression levels of the chemokine receptor CXCR4 in
inflammatory monocytes, possibly indicative for fueling the
inflammation during SARS-CoV-2-infection (51). As targeting
CXCR4 has been subject to intensive studies due to involvement
of the chemokine axis in tumor progression (52, 53), suitable
radiopharmaceutical conjugates of CXCR4 as well as potent
CXCR4 antagonists have been developed and thoroughly
described (54, 55) and thus could be easily repurposed to
investigate the cytokine signaling pathway in COVID-19 and
monitor possible effects of targeted therapy with CXCR4
antagonists by quantifying the regional level of CXCR4 activity
over time. Unlike lab findings mainly reflecting systemic
inflammatory activity, molecular imaging has the potential to early
identify the involvement of specific organs and monitor their
response to therapy.
ATP-Purinergic Receptor P2X7 Pathway
Another potent activator of the innate immune system related to
antiviral response that recently has come into focus, is the
purinergic receptor P2X7 (56–58), which is mainly expressed in
inflammatory and immune-related myeloid cells – macrophages
and microglia. P2X7 receptors are potent stimulants of
inflammation, mediating the activation of the NLRP3
inflammasome, as well as cytokine and chemokine release, thus
forming a natural target for anti-inflammatory therapy. A number
of radiopharmaceuticals selective to the P2X7 receptor have been
developed, are meanwhile well established, and have already been
put into clinical practice (59). While initially designed to quantify
neuroinflammation, they can easily be repurposed for imaging and
quantifying localized inflammation at a whole-body scale. As there
are also potential P2X7-inhibitors at receptor level, showing anti-
inflammatory effects in animal models (60), P2X7-receptor imaging
may here form the rationale for directing and monitoring anti-
inflammatory therapy in case of regional or systemic involvement in
COVID-19.
Postinflammatory Fibrosis
There is accumulating data that recovery after COVID-19 infection
can be associated with persistent organ damage induced by
postinflammatory fibrosis (61), and early detection of prolonged
fibroblast activation related to inflammation could warrant tailored
therapies directed at mitigation of fibrosis and an underlying
inflammatory process. Molecular imaging here could play a
critical role for understanding the extent of systemic disease and,
by visualizing, help to direct therapy and follow up therapy
response. One out of a number of possible molecular targets that
have gained considerable interest most recently, are the integrins,
which derive their name from which derive their name from their
role of integrating the extracellular matrix with the insoluble cellular
cytoskeleton. The field of integrin research was advanced
enormously by the detection of the crystal structure of the
extracellular domain of avb3 in 2001 (62). This structure shows
that the globular head of the integrin is made up of a seven-bladed
b-propeller contributed by the a-subunit and the A-domain from
the b-subunit together with an immunoglobulin fold, made up of
polypeptide sequences from either side of the b A-domain. The
integrin stalks are folded into three b-sandwich domains in the a
and four epidermal growth factor (EGF)-like repeats in the
b-subunit. The ligand-binding specificity of integrin molecules is
determined by the particular a–b combination and consequently
determines the adhesion specificity of different cell types. Recent
research has successfully led to radiolabeled avb6-binding peptides,
which are targeting an epithelium-specific cell surface receptor that
is low or undetectable in healthy adult epithelium but upregulated in
select injured tissues (63–65), where it has successfully been shown
by immunohistochemical analysis of biopsy specimens, that tissues
showing high uptake on 18F- avb6-BP PET/CT in patients with
cancer indeed correlated with high expression of integrin avb6 for
tissues (NCT03164486) (64). Following the call to repurpose well
characterized imaging biomarkers for COVID-19 research (66), the
same group recently proposed to extend the use of the
demonstrated integrin avb6 imaging agent 18F-avb6-BP to assess
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lung damage in patients after severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in a first-in-human study
(67). In their preliminary study, the authors were able to
demonstrate a correlation of integrin avb6-targeted 18F-avb6-BP
PET with lung damage identified by CT. The authors concluded in-
vivo integrin imaging to be a promising strategy to detect and
monitor the development and progression of lung fibrosis after
SARS-CoV-2 infection, with a better understanding of the nature of
the tissue remodeling and progression in recovering patients over
time being the key for developing therapeutic strategies to prevent
irrecoverably disease.
Another key protein for activation of the fibroblast cascade,
leading to destructive organ fibrosis, is the fibroblast activation
protein FAP (68), which has been studied for almost three decades.
As it has gained special attention as a highly expressed marker in
the vast majority of epithelial tumors, considerable amount of
research has been put into developing FAP-radioligands, resulting
in a number of radiolabeled FAP-antagonists suitable for whole-
body PET imaging (69). One of those radiolabeled imaging agents,
18-F-FAPI has just entered clinical oncologic imaging on the base
of large-scale clinical trials, with the potential of becoming the next
most used PET imaging agent besides FDG, as it has been shown
to prove diagnostic information for a multitude of different
tumor entities.
With novel FAP antagonists showing promising first results
to mitigate FAP induced fibrosis (70), the repurposing of FAP-
directed radiopharmaceuticals currently under extensive
investigation for oncology may open up a new door in




Other, still more experimental radiopharmaceuticals which
would prove useful in COVID-19 infection focus on directly
targeting the entry receptor for SARS-CoV-2, the angiotensin-
converting enzyme 2 (ACE-2)-receptor, involved in cellular
internalization of SARS-CoV-2 (71, 72) and, downstream, the
type 1 angiotensin-II-receptor ATR1 (e.g. KR31173). Numerous
reports have linked tissue specific ACE-2 expression to organ
injuries by ACE-2-mediated viral homing and attachment to
organ-specific cells, as well as to the role of ACE-2 bearing
macrophages potentially serving as trojan horse, triggering
pulmonal anchoring and migration out of the lung to other
tissues alike (73). Whole-body ACE-2-receptor imaging would
therefore provide a unique means to survey entry-points as well
as immunoreactivity during the course of COVID-19 infection.
Radiolabeling of ACE-2-receptor antagonists has been
achieved for receptor autoradiography protocols (74), and
could serve as starting point for a future PET tracer
development that would be able to provide quantitative data
on receptor based virus entry load in-vivo. Preclinical imaging of
ATR1 has also been successfully achieved using 11C- or 18F-
labeled compounds and preclinically available receptor
antagonists (75), which could be used to better define and
verify a point of pharmaceutical intervention.
Role of Cyclooxigenase-2 in COVID-19
Related Inflammatory Reaction
COX-2 is unexpressed under normal conditions in most cells,
and expression is stimulated via up-regulation of prostaglandins
during inflammation of various types. Non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit prostaglandin
production, Cyclocoxigenase-1 (COX-1) and COX-2. NSAIDs
selective for inhibition of COX-2 are commonly prescribed for
the control of fever and other symptoms in COVID-19 and
recently have come under scrutiny for anecdotal reports of
worsening the course of disease. In the current discourse of
controversial concepts of biological plausibility that possibly
leads to contradictory concepts of recommendations (76),
quantitative imaging of COX-2-involvement using established
COX-2-inhibitory radiopharmaceuticals (77) would lead the way
to provide evidence for general therapeutic guidelines or could
even inform individualized future treatment options.
Cell Tracking of CD-8+ T-Lymphocytes
T-lymphocytesandnatural killer (NK)-cellsplay critical roles inviral
clearance during respiratory infections. Recent reports of decreased
ratio of CD8+ T cells in COVID-19 patients may implicate a role of
CD8+Tcells in virus clearance (51),mostly at a later timepointof the
disease. CD8+ T-lymphocytes are preferred immune cells in cancer
immunotherapy, and extensive research already has gone into PET
imaging of cytotoxic human T cells, recently resulting in first-in-
human imaging studies of anti-CD-8 imaging in patients with solid
tumors (78). The application of novel radioligands with radioactive
half-time of more than 72 h allows for the concept of in-vivo cell
tracking of CD-8+ T-lymphocytes, which for clinical application in
solidmalignancies currently is in aPhase-II clinical trial (79). In-vivo
cell tracking of CD-8+ T-lymphocytes would therefore be available
indedicated research centers andcould contribute tomonitoring the
courseof immunedefenseduringCOVID-19 infectionandpossibly,
response to convalescentplasma therapy (80) or early immunization
trials. They also could prove helpful in tracking a possible
involvement of aberrant activation of CD-8+ T-lymphocytes in
multi-organ damage including cardiac injury, which will be of
increasing clinical importance with a steadily rising number of
reports on multi-organ involvement in COVID-19.
FUTURE PERSPECTIVES FOR
DEPICTING EVENTS AT EARLIER TIME
POINTS OF COVID-19
Proinflammatory chemokine receptor 2+ (CCR2+) macrophages
are importantmediators of inflammation during the early course of
COVID-19 and are therefore a potential target of interest for
quantitation of localized inflammation in the beginning of
infection with SARS-CoV-2. CCR2-binding peptides have been
labeled with 64Cu for use as PET radiotracer (64Cu-DOTA-ECL1i)
and have been successfully evaluated in a preclinical mouse model
of lung inflammation (81, 82). The very rapid blood clearance of
64Cu-DOTA-ECL1i, however,may possibly limit its practical use in
human studies, and further researchmay be necessary to adapt this
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promising PET probe to clinical needs in imaging early course of
inflammatory disease in humans.
Additionally to CCR2+monocytes, according to, IL-6 could also
be a target for PET probes at earlier time points of COVID-19. There
is, however, currently no conceptualized radiotracer targeting IL-6,
warranting further radiopharmaceutical research to fill this gap.
SUMMARY
Due to the still unfolding character of the COVID-19 pandemic,
only the lowest level of evidence for medical imaging (level V out
of five levels of evidence-based medicine criteria) is available, with
a consensus statement reached by a multidisciplinary expert panel
just recently jointly published by the American College of Chest
Physicians and the Radiological Society of North America and a
rapid advice guide published by the World Health Organization
(WHO) in June 2020. According to their statements, chest-CT is
regarded appropriate in patients with COVID-19 and worsening
respiratory status (83), and for symptomatic patients with
suspected COVID-19, when rt-PCR testing is not available or
delayed or when initial rt-PCR testing is negative, but a high
clinical suspicion of COVID-19 persists (84). With only limited
experience for other imaging modalities such as Ultrasound, MRI
and FDG-PET/CT, there are no evidence based criteria yet
allowing to recommend their use in COVID-19 on a routine base.
Molecular imaging, however, offers a potential clearly exceeding
the obvious primary clinical goal, to establish a correct diagnosis: it
offers tailored means to identify and quantify on cellular and
molecular levels important elements of the cascade of
immunological and immune-mediated events triggered by the
entrance of SARS-CoV-2 into the human body and to ultimately
predict at early timepoints the course of disease in an individual
patient, which would form the rationale for a patient-centric,
tailored therapeutic approach.
Limiting an early success of molecular imaging would be that
clinical manifestations of COVID-19 are complex and not all patients
are suffering the same symptoms—which would imply that clinicians
and immunologists should widely use molecular imaging for COVID-
19 and systematically investigate patients, defining and using those
molecular targets that are most promising for understanding the
course of disease and tailoring timely therapy to prevent sequelae and
death from this still devastating disease, taking into account asmuch of
interdisciplinary collaboration as possible and necessary.
While costs may also be considered a limiting factor for wide
application of molecular imaging, cost calculations would have to
take into account the potential of costs saved by preventing more
severe courses of disease, chronic disease and possible early
death. Considering that molecular imaging has been shown to
be cost-effective in a variety of cancer conditions (85–87), it is
conceivable that this might equally be the case for COVID-19,
where life expectancy and life quality without the event of
infection would be unimpaired. Allocation of research funds
would thus follow the same principles as in cancer research.
Undoubtedly, there is an urgent need for higher level of
evidence for medical imaging in COVID-19 and, subsequently,
for derived decisions on treatment approaches. As controlled
studies on COVID-19 patients will have to be performed in an
interdisciplinary setting and precautions to comply with for
medical procedures in these patients are high, any imaging
study should be designed in a way to generate the most
comprehensible data possible. Nuclear medicine procedures
using PET/CT and PET/MR are elegantly combining imaging
data from two modalities in a single imaging session, thus
reducing the number of patient visits and contact time under
extensive precautions. Besides providing new pathophysiological
insights of immune response in COVID-19 using molecular
probes, any PET/CT or PET/MR performed in these patients
will also provide fully diagnostic CT or MRI exams at the same
time, thus being able to answer clinical questions in need, and
according to current evidence. Additionally, as PET/CT and
PET/MR by design are intended to cover a whole-body
imaging field, nuclear medicine will be able to shed light on
the increasing number of extrapulmonary organ involvement
that we are just beginning to fully recognize. With the glucose
analog on FDG being the most available routine tracer for PET
imaging, an unspecific but highly sensitive probe for localized or
generalized inflammatory disease is readily and immediately
available, and given the improved sensitivity of the current
generation of PET/CT and PET/MRI scanners, these
procedures can be safely performed even in the youngest of
our patients and in the worst of their clinical conditions.
Tailored radiopharmaceuticals beyond FDG that already have
been established and thus can be made available with modest effort
will, on a short time-scale, allow to conduct controlled and
prospective studies of various levels on interaction of SARS-CoV-
2 related immunopathomechanisms, to better understand when
and where detrimental processes are being activated. This would
help to early diagnose critical organs at risk of inflammatory
destruction and to potentially guiding the observer on disease-
directed pharmacologic interventions according to receptor status,
biochemical status or receptor ligand status.
Institutionsprovidingoneof themost advancedwhole-bodyPET
scanners like theuEXPLORERatUCDavis or thePennPETExplorer
might spearhead clinical studies by their unique capability offast and
comprehensive whole-body dynamic and quantitative imaging and
of whole-body acquisition times in the range of seconds. PET/MRI
using dedicated tracers could prove to be helpful in cases of occult
myositis, endocarditis, myocardial inflammation, or myopathy, as
well as CNS involvement. A pictorial review of selected, possible
imaging targets and their relation tocurrent conceptsof therapeutical
interventions is given in Figure 1.
And finally, if further, specific targets of interest are discovered by
clinicians, appropriate biochemicalmarkers and radiopharmaceuticals
can be tailored to address the most imminent needs.
The examples on radiopharmaceuticals chosen here are not meant
to be comprehensive. They are meant to give a perspective and to
exemplify how certain steps of viral interaction within the human body
and its immune response can be quantitatively and longitudinally
assessed, potentially directly guiding specific treatment based on
evidence, using existing and well described radiopharmaceuticals that
are easily to be repurposed. The examples are also meant to stimulate
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the scientific community’s potential to contribute to one of the
biggest challenges in modern medicine and to plan and conduct
multicentric trials and to share what it needs for making novel
radiopharmaceuticals accessible at an accelerated time scale.
CONCLUSION
Molecular imaging repurposing molecular probes already
established in nuclear medicine have the immediate perspective
of facilitating evidence based medicine in COVID-19 by
providing in-vivo quantitative measures of molecular and
immunological mechanisms on a whole-body scale. To fulfill
this goal, immunologists and clinicians alike should widely use
molecular imaging as a longitudinal measure in future clinical
trials as well as in controlled patient cases. A prospective build-
up of a longitudinal molecular imaging database for COVID-19,
including pathological findings, lab measures, and clinical
follow-up will be key to identifying imaging biomarkers and
other predictive measures of prognostic significance.
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FIGURE 1 | Pictorial review highlighting selected molecular imaging targets for pathophysiological features of coronavirus disease 2019 (COVID-19) and their relation
to current concepts of therapeutical interventions, based on a schematic representation of the reproduction cycle of SARS-CoV-2 at the alveolus–host cell interface.
Radiopharmaceuticals (red italic) are depicted at their specific binding sites: receptor antagonists binding to their respective receptors, integrin ligands and FAPI-
antagonists schematically binding to their respective target structures. Intracellular therapeutic interventions (green) and systemic interventions (red) are shown for
their possible downstream effects that will influence the dependent functional imaging principle. Each diagnostic receptor binding site also represents a possible
therapeutic target site, thus any therapeutic use of receptor antagonists intrinsically forms a displacement challenge for its diagnostic twin, allowing a direct
quantitation of localized therapeutic receptor binding.
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